Since KRAS G12C mutation is relatively rare in advanced CRC, developing therapeutics to inhibit a wider variety of KRAS inhibition is needed to improve further the treatment for KRAS mutated CRC. This evidence concerns the gene KRAS and colorectal carcinoma.